We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Renal Denervation in Patients With Uncontrolled Hypertension in Chinese

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2011 by The Second People's Hospital of Chengdu.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01390831
First Posted: July 11, 2011
Last Update Posted: July 11, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
The Second People's Hospital of Chengdu
  Purpose
The purpose of this study is to determine whether renal denervation is safe and effective in the treatment of Chinese patients with uncontrolled hypertension.

Condition Intervention Phase
Hypertension Device: THERMOCOOL® Catheter Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Renal Denervation in Patients With Uncontrolled Hypertension in Chinese

Further study details as provided by The Second People's Hospital of Chengdu:

Primary Outcome Measures:
  • Blood Pressure Reduction [ Time Frame: one year ]
    To confirm that renal denervation is safe, feasible and effective.


Estimated Enrollment: 100
Study Start Date: November 2011
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Catheter, Renal Denervation, Ablation
Catheter-based renal denervation and maintenance of anti-hypertensive medications
Device: THERMOCOOL® Catheter
Catheter-based renal denervation
No Intervention: anti-hypertensive medications
Maintenance of anti-hypertensive medications

Detailed Description:
Prevalence of hypertension is increasing in China.While actually,the controlled rate of hypertension is relatively low,though numerous safe and effective pharmacological therapies are used in clinical practice.Studies confirmed that renal sympathetic nerves contributed to development and perpetuation of hypertension. Previous study has stated that renal denervation was effective and safe in patients with resistant hypertension, while little data is known in Chinese patients. We hypothesis that renal denervation is effective and safe in treatment of Chinese patients with uncontrolled hypertension. This trial plan to recruit 100 patients(Ablation group VS Control group = 1:1) with a follow up duration of 3 years.Patients in ablation group will receive percutaneous renal denervation combined with necessary antihypertension drugs and patients in control group will receive appropriate antihypertension drugs. We aim to explore the long term safety and validity of renal denervation in Chinese patients with uncontrolled hypertension.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • >= 18 years of age
  • a systolic blood pressure of 160mmHg or more and/or a diastolic blood pressure of 90mmHg or more
  • receiving and adhering to at least three full doses of appropriate antihypertensive drug regimen
  • estimated glomerular filtration rate (eGFR) of ≥45mL/min
  • agrees to have the study procedure(s) performed and additional procedures and evaluations
  • is competent and willing to provide written, informed consent to participate in this clinical study

Exclusion Criteria:

  • secondary hypertension
  • renal arterial abnormalities
  • has experienced MI, unstable angina pectoris, or CVA within 6 months
  • has an implantable cardioverter defibrillator (ICD) or pacemaker, or any other metallic implant which is not compatible with magnetic resonance imaging (MRI)
  • requires respiratory support
  • patients with sick sinus syndrome
  • pregnant woman
  • others
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01390831


Contacts
Contact: Jian Xiong Liu, MD 862886621522-5205 steven.ljx@163.com

Sponsors and Collaborators
The Second People's Hospital of Chengdu
Investigators
Principal Investigator: Jian Xiong Liu The Second People's Hospital of Chengdu
  More Information

Responsible Party: Jian-xiong LIU, The Second People's Hospital of Chengdu
ClinicalTrials.gov Identifier: NCT01390831     History of Changes
Other Study ID Numbers: 2011SZ0118
First Submitted: July 6, 2011
First Posted: July 11, 2011
Last Update Posted: July 11, 2011
Last Verified: April 2011

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents